Cidara Therapeutics (CDTX) Given Media Impact Score of 0.09
News articles about Cidara Therapeutics (NASDAQ:CDTX) have trended somewhat positive on Sunday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cidara Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment’s rankings:
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Stock Rating Upgraded by ValuEngine (americanbankingnews.com)
- 13G Filing: Broadfin Capital and Cidara Therapeutics Inc. (CDTX) (insidermonkey.com)
- Zacks Investment Research Downgrades Cidara Therapeutics, Inc. (CDTX) to Hold (americanbankingnews.com)
- Zacks Investment Research Upgrades Cidara Therapeutics, Inc. (CDTX) to “Buy” (americanbankingnews.com)
Cidara Therapeutics (NASDAQ CDTX) traded up 6.21% during midday trading on Friday, reaching $7.70. 142,950 shares of the company were exchanged. The stock’s market capitalization is $129.41 million. Cidara Therapeutics has a 52 week low of $5.65 and a 52 week high of $12.95. The firm’s 50 day moving average price is $6.74 and its 200-day moving average price is $8.12.
Cidara Therapeutics (NASDAQ:CDTX) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.10. Equities analysts forecast that Cidara Therapeutics will post ($3.46) EPS for the current fiscal year.
CDTX has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Cidara Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, March 20th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Cidara Therapeutics in a research report on Friday, March 24th. Cantor Fitzgerald restated a “buy” rating on shares of Cidara Therapeutics in a research report on Friday, April 7th. Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Cidara Therapeutics in a research report on Monday, April 10th. Finally, Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Cidara Therapeutics in a research report on Monday, April 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Cidara Therapeutics currently has an average rating of “Buy” and an average target price of $12.41.
In other Cidara Therapeutics news, insider Taylor Sandison acquired 20,000 shares of the company’s stock in a transaction on Wednesday, June 7th. The shares were bought at an average cost of $5.90 per share, for a total transaction of $118,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey Stein acquired 15,000 shares of the company’s stock in a transaction on Monday, June 5th. The shares were acquired at an average price of $5.95 per share, for a total transaction of $89,250.00. The disclosure for this purchase can be found here. 18.90% of the stock is owned by insiders.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Stock Ratings for Cidara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc and related stocks with our FREE daily email newsletter.